Rigel Pharmaceuticals (RIGL) Equity Average (2011 - 2026)

Rigel Pharmaceuticals' Equity Average history runs 16 years deep, the most recent figure standing at $395.7 million for Q1 2026.

• In Q1 2026, Equity Average rose 3521.03% year-over-year to $395.7 million; the TTM figure through Mar 2026 stood at $395.7 million (up 3521.03% YoY), while the FY2025 annual figure was $197.4 million, up 1656.9% from the prior year.
• Equity Average was $395.7 million for Q1 2026 at Rigel Pharmaceuticals, up from $254.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $395.7 million in Q1 2026 to a low of -$30.8 million in Q2 2024.
• Historically, Equity Average has averaged $35.8 million across 5 years, with a median of -$11.8 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Equity Average sank 1778.05% in 2023, then soared 4586.16% in 2025.
• A 5-year view of Equity Average shows it stood at -$16.7 million in 2022, then slumped by 80.8% to -$30.2 million in 2023, then surged by 81.24% to -$5.7 million in 2024, then jumped by 4586.16% to $254.5 million in 2025, then jumped by 55.45% to $395.7 million in 2026.
• The last three Equity Average figures came in at $395.7 million (Q1 2026), $254.5 million (Q4 2025), and $99.8 million (Q3 2025), per Business Quant data.